Eloxatin

Manufacturer country

France

Pharm Group

Alkylating agents, platinum derivatives

Manufacturers

Sanofi Winthrop Industries (France)

International name

Oxaliplatin

Synonyms

Oxatera

Dosage forms

lyophilized powder for the preparation of injection solution 100 mg, lyophilized powder for the preparation of injection solution 50 mg

Compound

The active substance is oxaliplatin.

Indications for use

Metastatic colorectal cancer in combination with fluoropyrimidines or, if possible, in combination with them; ovarian cancer.

Contraindications

Hypersensitivity (including to other drugs containing platinum), pregnancy, lactation.

Side effect

Headache, dizziness, drowsiness, convulsions, general weakness, peripheral sensory neuropathy, dysesthesia of the perioral region, upper respiratory tract and gastrointestinal tract, visual impairment; loss of appetite, nausea, vomiting, gastrointestinal bleeding, diarrhea, liver dysfunction; myelodepression (leukopenia, granulocytopenia, thrombocytopenia, anemia), bleeding and hemorrhage; hyperthermia, development of infections, rash, facial hyperemia, pneumosclerosis, pulmonary infiltration, sexual dysfunction, teratogenicity, embryotoxicity, allergic reactions, incl. anaphylactoid.

Interaction

Pharmaceutically incompatible with aluminum salts. Reduces the effectiveness of immunization with inactivated vaccines; When using vaccines containing live viruses, it increases viral replication and side effects of vaccination. Incompatible with alkaline saline solutions containing chlorides and other drugs in the same infusion system. Potentiates the neurotoxic effect of other antitumor drugs, myelosuppression induced by myelotoxic drugs and radiation therapy. Compatible in combinations with other antitumor drugs.

Overdose

Symptoms: increased side effects. Treatment: symptomatic therapy; if necessary, transfusion of blood components, prescription of broad-spectrum antibiotics; monitoring of vital functions.

special instructions

Use is only possible under the supervision of a physician experienced in chemotherapy. Before and during treatment (at short intervals), it is necessary to determine the level of blood cells and conduct a full neurological examination. In order to relieve dyspeptic symptoms (nausea, vomiting), it is necessary to prescribe antiemetics. If diarrhea develops, it is necessary to increase fluid intake. It is necessary to exclude contact with infectious patients or use nonspecific measures for prevention (protective mask, etc.). During treatment, it is recommended to use adequate contraception. In case of contact of the drug with skin or mucous membranes, thorough rinsing with water is necessary. Dissolution, dilution and administration of the drug is carried out by trained medical personnel in compliance with protective measures (gloves, masks, clothing). When used in combination with fluoropyrimidines, it is administered before them. Do not use undiluted solutions. The infusion system should be flushed after administration of oxaliplatin before using it to administer other drugs.

Literature

Encyclopedia of drugs 2006